The role of γδ T cells in the context of allogeneic stem cell transplantation

Rupert Handgretinger1,2*, Peter Lang1, Manon Queudeville1

1Department of Hematology/Oncology, Children’s University Hospital of Tuebingen, 72076 Tuebingen, Germany
2Current address: Abu Dhabi Stem Cell Center, Abu Dhabi, UAE

*Correspondence: Rupert Handgretinger, Department of Hematology/Oncology, Children’s University Hospital of Tuebingen, Hoppe-Seyer-Strasse 1, 72076 Tuebingen, Germany. Rupert.Handgretinger@med.uni-tuebingen.de

Academic Editor: Dieter Kabelitz, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein Campus Kiel, Germany

Received: November 29, 2021 Accepted: January 26, 2022 Published: March 16, 2022

Cite this article: Handgretinger R, Lang P, Queudeville M. The role of γδ T cells in the context of allogeneic stem cell transplantation. Explor Immunol. 2022;2:157–67. https://doi.org/10.37349/ei.2022.00041

Abstract

Allogeneic stem cell transplantation is currently the only curative approach for a variety of malignant and non-malignant diseases. In the early transplant era, the intent of this treatment was to apply an intensive myeloablative regimen to eliminate residual malignant cells followed by the hematopoietic rescue of the patients with donor hematopoietic stem cells. However, the focus has shifted over time and allogeneic transplantation is nowadays seen as a cellular therapy in which the donor-derived immune system mounts an anti-infectious and especially an anti-tumor effect in the posttransplant phase. In order to further augment the anti-tumor effect, various approaches have been developed, including the manipulation of the donor-derived immune system in vivo or the adoptive transfer of ex vivo-expanded donor-derived effector cells. Based on their lack of alloreactivity, γδ+ T cells are shifting into the spotlight of research in the context of allogeneic transplantation. Their exploitation with regard to their anti-infectious and anti-tumor properties and their in vivo and ex vivo manipulation will lead to new therapeutic approaches to improve the outcome of patients after allogeneic stem cell transplantation. In this review, the important role of γδ+ T cells in allogeneic matched and mismatched transplantation is summarized and an outlook is discussed on how to best make use of this unique cell population.

Keywords

Allogeneic stem cell transplantation, γδ T cells, immunotherapy, adoptive transfer, chimeric antigen receptor T cells

Introduction

Despite the rise of new cellular therapies such as chimeric antigen receptor (CAR) T cells, allogeneic (allo) stem cell transplantation (SCT; allo-SCT) remains the only curative treatment for many patients with various hematological malignancies. In the early beginnings, allo-SCT was accompanied by a high risk of often lethal complications, including organ toxicity induced by the myeloablative conditioning, graft-versus-host disease (GVHD), infections due to the delayed immune reconstitution and relapses of the underlying diseases.
However, tremendous progress has been made over time to reduce the side effects of allo-SCT. Advances in the prophylaxis and treatment of GVHD as well as a better understanding of the important role of the immune reconstitution have led to a significant decrease of the complications seen after transplantation and the numbers of allogeneic transplantation are steadily increasing [1].

Allo-SCT therapy was initially only offered to patients who had a human leukocyte antigen (HLA)-matched related or unrelated donor. Since not all patients had an HLA-suitable donor, attempts were made to offer these patients a transplant from a related haploidentical donor. Unfortunately, these early haploidentical transplantations were accompanied by severe and often lethal GVHD [2].

However, approaches to avoid GVHD by either ex vivo T cell depletion [3, 4] or the use of post-transplant cyclophosphamide (PTCy) [5] have revolutionized the field and the number of haploidentical transplantation is rising [6]. Therefore, almost every patient in need of a transplant can nowadays be offered this often only curative approach.

As already mentioned, a better understanding of the immune reconstitution is important for a better outcome with respect to decreasing the risk of severe and lethal viral and bacterial infections post-transplant and maybe also to decreasing the risk of relapse of the underlying malignant disease [7]. In this regard, allo-SCT is nowadays regarded as a cellular therapy rather than just a myeloablative chemo/radiotherapy to ultimately destroy the malignant cells. The immune recovery of various immune effector cells, such as natural killer (NK) cells and especially T cell receptor (TCR) αβ⁺ T-lymphocytes play an important role in fighting infections post-transplant and also in decreasing the risk of relapses. γδ T cells are also an important effector cell population in allogeneic transplantation [8] and have moved into the focus of research [9]. In contrast to TCRαβ⁺ T cells, γδ T cells are not alloreactive, will not cause GVHD, and can have many positive effects in allogeneic transplantation [10]. Therefore, the manipulation of γδ T cells might become a powerful tool to improve the outcome of patients after allogeneic transplantation. Their role in immune reconstitution, their adoptive transfer and/or their in vivo stimulation will be discussed in this review.

The role of γδ T cells in immune reconstitution after allogeneic transplantation

Although increased numbers of γδ T cells were found in early studies of patients who developed acute GVHD after allo-SCT [11], later studies did not support these findings and no significant correlation between γδ T cells and the incidence of GVHD in the first 12 months posttransplant was reported in a later study [12]. In patients who received an ex vivo TCRαβ T cell-depleted bone marrow from partially HLA-mismatched donors, a significantly better disease-free survival (DSF) at 30 months posttransplant was observed in patients in whom the percentage of γδ T cells was more than 10% of the total lymphocyte count. There was no difference in the incidence of acute or chronic GVHD [13]. In an extended 42-month follow-up study, the authors confirmed their data [14]. A further follow-up study 8 years later with an increased number of patients (n = 153) revealed a higher 5-year leukemia-free and overall survival in patients who reconstituted with a higher number of γδ T cells [15].

Minculescu et al. [16] reported on an improved overall survival, relapse-free survival, and less GVHD in patients with fast immune reconstitution of γδ T cells 2 months after allo-SCT [16]. These results suggest a protective role of γδ T cells against relapse and interestingly also GVHD. It is of interest in this context that granulocyte-colony stimulating factor (G-CSF) participates in acute GVHD regulation by inducing T-regulatory γδ T cells including Vδ1 regulatory T cells (Tregs), CD27⁺Vδ1 Tregs and CD25⁺Vδ1 Tregs [17]. In a murine graft-versus-leukemia (GVL) and acute GVHD model, Song et al. [18] demonstrated that γδ T cells were critical in mediating GVL effects and that γδ T cells also mitigated acute GVHD by suppressing CD4⁺T cell activation [18].

In a recent study, Klyuchnikov et al. [19] showed that the enhanced immune reconstitution of γδ T cells after allo-SCT overcomes the negative impact of pre-transplant minimal residual disease (MRD) positive status in adult patients suffering from acute myeloid leukemia (AML) [19]. The authors investigated the potential GVL effect of γδ T cells in 100 patients with positive MRD pre-transplant. Younger age (≤ 58 years)
of recipients and donors (< 30 years), sex mismatch, matched donors, cytomegalovirus (CMV) reactivation and anti-thymocyte globulin (ATG) were associated with a faster reconstitution of γδ T cell. A multivariate analysis of the MRD+ patients who had a higher than median γδ T cell count on days +30 and +100 posttransplant revealed that these patients had a significantly improved leukemia-free and overall survival. Moreover, higher levels of γδ T cells at day +30 were associated with a significantly reduced risk of relapse. Interestingly, patients who received PTCy for GVHD prophylaxis had a lower posttransplant level of γδ T cells compared to patients who received ATG. No impact of the γδ T cell level was seen in MRD-negative patients and no correlation with the development of GVHD was observed.

Similar to NK cells, γδ T cells express inhibitory HLA receptors [20]. Dolstra et al. [21] showed that Vγ9Vδ1 T cells derived from peripheral blood of an AML patient after allo-SCT lysed freshly isolated AML blasts and AML cell lines and that the cytotoxic function of the γδ T cells was negatively regulated by the inhibitory immunoglobuline-like receptor (KIR) CD158b [21]. It is currently unknown whether alloreactive or non-alloreactive γδ T cells based on their KIR expression have an important role in the setting of allogeneic and especially in haploidentical transplantation, as it has been described for KIR-expressing NK cells [22]. In a study with pediatric patients with leukemia, the number of γδ T cells was determined after allogeneic transplantation including haploidentical transplantation with ex vivo T cell-depleted mobilized peripheral stem cells grafts [23]. Patients with a higher γδ T cell level had a significantly better event-free and overall survival within a median follow-up period of 2.7 years. Moreover, a lower incidence of bacterial and viral infections was seen in these patients, pointing towards an important anti-bacterial [24] and antiviral function [25] of γδ T cells. It is of interest in this context that especially the Vδ2neg subset expands upon reactivation of the CMV and that CMV-induced γδ T cells can recognize and lyse primary leukemic blasts [26]. One could speculate that this might be an explanation for the observation that early CMV replication posttransplant is associated with a decreased relapse risk in patients with AML [27]. It has also been shown that Epstein-Barr virus (EBV) infections posttransplant lead to an expansion of Vδ1+ T cells in a patient with acute lymphoblastic leukemia (ALL) and this subset represented more than 80% of the circulating γδ T cells [28]. In a more detailed analysis of the dynamics of the repertoires of γδ T cell antigen receptors before and after transplantation, Ravens et al. [29] showed that patients had a rapid γδ T cell reconstitution posttransplant and that they had profoundly altered TCR repertoires. Of interest, the clonal proliferation of virus-reactive γδ TCR sequences in patients with CMV reactivation hinted towards an adaptive anti-viral γδ T cell immune response [29]. In addition, Liu et al. [30] found an inverse correlation of Vδ2+ T cell recovery with EBV reactivation after allo-SCT. They also reported that immunosuppressive therapy for GVHD prophylaxis had a negative effect on the anti-EBV capacity of the Vδ2+ T cells and that strategies to reduce or omit immunosuppression posttransplant may improve the anti-EBV immunity by increasing the activity of the Vδ2+ subset [30]. Another evidence for the overall importance of γδ T cells in allo-SCT comes from a systematic review and meta-analysis by Arruda et al. [31]. These authors searched 2,412 studies, of which 11 studies with 919 patients were eligible for meta-analysis. They found that high γδ T cell levels after allo-SCT were significantly associated with a lower risk of relapse, with fewer episodes of viral infections and with a better overall and DFS. It is of importance in this context that they did not find an association between high γδ T cell counts and acute GVHD incidence.

The role of γδ T cells in the context of ex vivo T cell depleted transplantation
Most of the so far described results have mainly been observed in patients who received an unmanipulated bone marrow or peripheral blood stem cell (PBSC) grafts mobilized with G-CSF and a subsequent posttransplant GVHD prophylaxis. In the context of ex vivo T cell-manipulated grafts and in the absence of any GVHD prophylaxis, the role of γδ T cells might become even clearer than already described. The initial ex vivo T cell depletion methods comprised the isolation of CD34+ stem cells from G-CSF mobilized PBSC [3] or the depletion of CD3+ T cells [32]. Both of these methods were associated with the co-depletion of γδ T cells and no clear picture regarding the role of γδ T cells in this setting emerged. In order to use the potential anti-leukemic and anti-infectious effects of donor-derived γδ T cells, the TCRαβ depletion of mobilized
PBSCs was introduced \[33\]. This method is associated with a high log depletion of TCRαβ+ T cells while retaining high numbers of NK and γδ T cells in the mobilized PBSC grafts. Due to the high depletion efficacy of this method, only a short or no posttransplant pharmacological GVHD prophylaxis is necessary.

The mobilization of peripheral donor stem cells with G-SCF does not impair the function of γδ T cells. This was shown by Otto et al. \[34\] who demonstrated that the γδ T cells in the G-SCF mobilized grafts retain a strong tumoricidal activity and produce immunomodulatory cytokines including interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) \[34\]. They also observed a high proportion of Vγ9Vδ1 T cells in some of the G-SCF mobilized grafts. This finding was recently confirmed by Minculescu et al. \[35\] in a more detailed analysis of the influence of G-SCF on the mobilization of γδ T cell subsets in healthy stem cell donors \[35\]. They found that G-SCF preferentially mobilized naive and terminally differentiated CD45RA re-expressing effector memory T cells (termed TEMRA) cells over memory cells and that G-SCF preferentially mobilized cells of the nonVδ2 types and increased the fraction of HLA-DR positive γδ T cells. The highest increase of γδ subsets was of the Vδ1 and nonVδ1-nonVδ2 type. The Vδ1 subset of γδ T cells is of special interest since it was shown that this subset is associated with the effective killing of fresh AML blasts after allo-SCT \[21\].

Various studies have been performed in pediatric and adult patients using the ex vivo TCRαβ depletion with or without concomitant depletion of CD19+ B lymphocytes in a matched related or unrelated and haploidentical setting. In a prospective multicenter study of TCRαβ and CD19 depleted haploidentical SCT in pediatric and adult patients, it was shown that despite the co-infusion of a median of 10.4 × 10^6/kg body weight (BW, range 1.1–45 × 10^6) T cells, the incidence of acute GVHD was low and none of the patients included both Vδ2+ and Vδ2– cells. Lang et al. \[38\] observed an improved immune recovery after TCRαβ depleted haploidentical SCT in children \[38\]. The median number of co-transplanted γδ T cells was 11 × 10^6/kg BW with a wide range of 0.9–89.7 × 10^6/kg BW. The recovery of donor-derived γδ T cells started as early as day +7 and preceded the recovery of αβ+ T cells. A similar observation was made in pediatric patients with AML who received TCRαβ depleted PBSC grafts from matched unrelated and haploidentical donors \[39\]. A more detailed analysis of the reconstituting γδ T cells was reported by Airoldi et al \[40\]. They analyzed the γδ subsets in 27 pediatric patients after receiving TCRαβ depleted PBSC grafts. The median number of co-transplanted γδ T cells was 7.85 × 10^6/kg BW (range 1.5–94.5 × 10^6/kg BW). The majority of the reconstituting CD3+ T lymphocytes 2 to 4 weeks posttransplant were γδ T cells, preceding the recovery of TCRαβ+ T cells and a higher number of infused γδ T cells was associated with a later increase of αβ+ T cells. Among the reconstituting γδ T cells, mainly 3 subsets were seen, namely Vδ1+, Vδ2+, and Vδ1negVδ2neg T cells. Four weeks after transplantation, the mean percentages for Vδ1+, Vδ2+, and Vδ1negVδ2neg were 65%, 25%, and 9.6%, respectively. They then compared the γδ recovery with pediatric patients who received a CD34+ positively selected graft. Three months posttransplant, the level of γδ T cells was lower in the CD34+ cohort and most of the cells were of the Vδ1 phenotype. In patients who had a CMV reactivation, a significant increase of Vδ1+ T cells was observed \[40\]. Bertaina et al. \[41\] reported interesting data in pediatric patients on the in vivo activation of γδ T cells posttransplant after receiving a TCRαβ depleted PBSC graft. Zoledronate was given to 43 patients with ALL (n = 30) and AML (n = 13) every 28 days and most patients received two applications. Zoledronate induced an increase of the Vδ2 subset and an increase of the cytotoxicity against primary leukemic blasts. Moreover, patients who received 3 or more infusions of zoledronate had a better probability of survival compared to patients who received only 1 or 2 infusions (86% versus 54%, P = 0.008) \[41\]. In an extended study, Merli et al. \[42\] treated 46 patients with leukemia after TCRαβ depleted SCT in the absence of any immunosuppressive pharmacological GVHD prophylaxis with monthly infusions of zoledronate starting at day +20 posttransplant. A total of 139 infusions with a mean of 3 infusions per patient were given. No adverse effects were observed and patients receiving...
repeated infusions had lower transplant-related mortality (TRM) compared to those receiving only 1 or 2 applications of the drug (0% versus 16.7%, $P = 0.01$). Multivariate analysis revealed an independent positive effect on the outcome induced by repeated infusion of zoledronate [42].

**Possible therapeutic exploitation of donor γδ T cells in allogeneic transplantation**

Based on the available data one can safely assume that allogeneic γδ T cells are not alloreactive, neither in the HLA matched related/unrelated nor in the haploidentical setting. Therefore, γδ T cells are attractive candidates for posttransplant therapeutic strategies in allogeneic transplantation aiming to reduce the risk of infections and the risk of relapses of the underlying diseases. The *in vivo* activation of γδ T cells posttransplant, as already shown for zoledronate, could be one approach to exploit the anti-tumor and anti-infectious capacity of this cell population. Another approach could be the posttransplant adoptive transfer of donor-derived γδ T cells or subpopulations [43].

Besides zoledronate, various other agents including interleukin 7 (IL-7) and IL-15 have been identified [44–46] to induce the expansion of γδ T cells or subsets (for review see [47]). The ability of γδ T cells to exert an effective antibody-dependent cellular cytotoxicity (ADCC) via their expression of the CD16 Fc receptor could additionally contribute to their anti-leukemic activity [48–50] and the early *in vivo* use of anti-tumor antibody could be a strategy to activate γδ T cells and NK cells posttransplant, since these are the first lymphocytes to emerge after transplantation of T cell depleted grafts. Such a strategy has been described [51] and warrants further prospective clinical trials.

Only a few *in vivo* studies are currently performed which aim to stimulate γδ T cells in the haploidentical posttransplant setting. In one study, zoledronate is given posttransplant in patients receiving a TCRαβ depleted haploidentical graft (study identifier: NCT02508038), and in the other study, the combination of zoledronate and IL-2 is administered posttransplant in patients after haploidentical T-replete transplantation (NCT03862833).

Some studies are currently performed aiming at the *ex vivo* expansion of donor-derived γδ T cells with subsequent adoptive transfer in patients after allogeneic transplantation. In these early phase clinical studies, donor γδ T cells are stimulated and expanded *ex vivo* and infused to the patients with malignant hematological diseases after allo-SCT (NCT03885076, NCT04008381, NCT04028440, NCT03533816). It is currently not clear which subset of the γδ T cells would be superior for adoptive transfer posttransplant. The Vδ2 subset can be activated and expanded using synthetic phosphoantigen or bisphosphonates [52]. Once activated, Vδ2 cells produce pro-inflammatory cytokines such as IFN-γ and TNF-α. Most of the peripheral γδ T cells are of the Vγ9Vδ2 subset and these cells can exert a potent and broad anti-tumor cytotoxicity in an HLA-independent manner. In addition, they are resilient to the suppressive action of programmed cell death-1 (PD-1) and can co-activate NK cells [53]. Vδ1 γδ T cells are the second most frequent subset in the peripheral blood. These cells mainly reside in mucosal epithelial tissue and also display potent anti-tumor activity [54]. Various approaches have been described to *ex vivo* expand Vδ1 cells [55]. Based on the lack of alloreactivity, γδ T cells would constitute an ideal tool for donor-derived CAR T cell therapy posttransplant. Rozenbaum et al. [56] described a 14-day procedure to produce anti-CD19 γδ CAR T cells from peripheral blood mononuclear cells from healthy donors with a median expansion of 185-fold. The transduction efficiency was 60.5% ± 13.2%. The cells were effective against CD19 positive targets *in vitro* and in an *in vivo* mouse model. Interestingly, multiple injections and priming of the γδ CAR T cells with zoledronate increased their *in vivo* anti-tumor function. Based on the natural cytotoxicity of γδ T cells, the anti-CD19 γδ CAR T cells were also able to lyse CD19 negative targets, which was further enhanced by priming the CAR cells with zoledronate [56].

Another approach to manufacture large numbers of γδ CAR T cells of the Vδ1 phenotype is described by Nishimoto et al. [57]. Nishimoto describes the use of an agonistic monoclonal antibody (mAb) that selectively activates and expands Vδ1 γδ T cells in healthy donor-derived peripheral mononuclear cells to achieve clinically relevant yields. Once activated, Vδ1 γδ T cells are transduced with a self-inactivating, replication-incompetent gamma-retroviral vector to express a CD20 CAR. After transduction, γδ T cells are
further expanded in culture, enriched by TCRαβ depletion, and then formulated for cryopreservation. This process has also been used to support the production of multiple CAR γδ T cell products expressing glypican-3 (GPC-3)-targeted CARs [58, 59].

A first-in-class clinical study using off-the-shelf third-party anti-CD20 Vδ1 CAR T cells is currently underway in patients with lymphoma (NCT04735471). Since the adoptive transfer of allogeneic donor-derived TCRαβ+ T cells might be associated with an increased risk of GVHD, donor-derived Vδ1 γδ CAR T cells manufactured with this method could be a powerful effector cell population, and clinical studies using posttransplant donor γδ CART cells are warranted.

Conclusions
It is commonly accepted that allo-SCT can be regarded as an effective form of cellular therapy. Many effector cell populations including NK cells, TCRαβ+ T cells, and γδ+ T cells may play together to exert a strong anti-tumor effect posttransplant. It is therefore important to analyze the individual contributions of each of these cell populations in order to maximize their therapeutic efficacy. In contrast to TCRαβ T cells, γδ T cells are, similar to NK cells, not alloreactive and therefore an interesting target for further augmenting their anti-infectious and anti-tumor properties posttransplant. Especially in the absence of posttransplant pharmacological immunosuppressive prophylaxis for GVHD, they can be activated in vivo with various drugs and cytokines, even in the haploidentical setting. The lack of alloreactivity also allows the adoptive transfer of ex vivo activated and expanded γδ+ T cells as well as the posttransplant application of donor-derived γδ CAR T cells. However, future research must also investigate the potential suppressive activity of adoptively transferred γδ T cells. In Figure 1, various possible approaches are summarized. Hopefully, these approaches will lead to an improvement of the outcome of allogeneic transplantation by reducing the infectious complications and more importantly by reducing the risk of relapses of the underlying malignant diseases.

**Figure 1.** Different approaches to how to exploit γδ T cells in a platform of TCRαβ-depleted SCT are suggested. Since there is no GVHD prophylaxis necessary, the in vivo and ex vivo treatment can be started early after transplant when the first donor-derived γδ and NK cells reappear.

**Abbreviations**

- allo-SCT: allogeneic stem cell transplantation
- AML: acute myeloid leukemia
- BW: body weight
- CAR: chimeric antigen receptor
- CMV: cytomegalovirus
Declarations

Acknowledgments
The authors acknowledge the continuous support of the Elternverein and Stiftung für krebskranke Kinder Tübingen e.V.

Author contributions
All authors contributed to the literature search. RH wrote the first draft. All authors contributed to the manuscript and read and approved the submitted version.

Conflicts of interest
RH is a co-patient holder of the TCRαβ depletion technology together with the Miltenyibiotec company. The other authors declare that they have no conflict of interest.

Ethical approval
Not applicable.

Consent to participate
Not applicable.

Consent to publication
Not applicable.

Availability of data and materials
Not applicable.

Funding
Not applicable.

Copyright
© The Author(s) 2022.
References

1. Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2021;[Epub ahead of print].

2. Powles RL, Morgenstern GR, Kay HE, McElwain TJ, Clink HM, Dady PJ, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet. 1983;1:612–5.

3. Schumm M, Lang P, Taylor G, Kuçi S, Klingebiel T, Bühring HJ, et al. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the ClinMACS device. J Hematother. 1999;8:209–18.

4. Handgretinger R. Negative depletion of CD3+ and TcRαβ+ T cells. Curr Opin Hematol. 2012;19:434–9.

5. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50.

6. D’Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26:e177–82.

7. Simons L, Cavazzana M, André I. Concise review: boosting T-cell reconstitution following allogeneic transplantation-current concepts and future perspectives. Stem Cells Transl Med. 2019;8:650–7.

8. Daniele N, Scerpa MC, Caniglia M, Bernardo ME, Rossi C, Ciammetti C, et al. Transplantation in the onco-hematology field: focus on the manipulation of οβ and γδ T cells. Pathol Res Pract. 2012;208:67–73.

9. Handgretinger R, Schilbach K. The potential role of γδ T cells after allogeneic HCT for leukemia. Blood. 2018;131:1063–72.

10. Hu Y, Cui Q, Luo C, Luo Y, Shi J, Huang H. A promising sword of tomorrow: human γδ T cell strategies reconcile allo-HSCT complications. Blood Rev. 2016;30:179–88.

11. Viale M, Ferrini S, Baccigalupo A. TCR gamma/delta positive lymphocytes after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1992;10:249–53.

12. Cela ME, Holladay MS, Rooney CM, Richardson S, Alexander B, Krance RA, et al. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996;17:243–7.

13. Lamb LS Jr, Henslee-Downey PJ, Parrish RS, Godder K, Thompson J, Lee C, et al. Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother. 1996;5:503–9.

14. Lamb LS Jr, Gee AP, Hazlett Lj, Musk P, Parrish RS, O’Hanlon TP, et al. Influence of T cell depletion method on circulating gammadelta T cell reconstitution and potential role in the graft-versus-leukemia effect. Cytotherapy. 1999;1:7–19.

15. Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, et al. Long term disease-free survival in acute leukemia patients recovering with increased γδ T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 2007;39:751–7.

16. Minculescu L, Marquart HV, Ryder LP, Andersen NS, Schjoedt I, Friis LS, et al. Improved overall survival, relapse-free-survival, and less graft-vs.-host-disease in patients with high immune reconstitution of TCR gamma delta cells 2 months after allogeneic stem cell transplantation. Front Immunol. 2019;10:1997.

17. Xuan L, Wu X, Qiu D, Gao L, Liu H, Fan Z, et al. Regulatory γδ T cells induced by G-CSF participate in acute graft-versus-host disease regulation in G-CSF-mobilized allogeneic peripheral blood stem cell transplantation. J Transl Med. 2018;16:144.

18. Song Y, Zhu Y, Hu B, Liu Y, Lin D, Jin Z, et al. Donor γδT cells promote GVL effect and mitigate aGVHD in allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:558143.
19. Klyuchnikov E, Badbaran A, Massoud R, Fritsche-Friedland U, Janson D, Ayuk F, et al. Enhanced immune reconstitution of γδ T cells after allogeneic stem cell transplantation overcomes the negative impact of pretransplantation minimal residual disease-positive status in patients with acute myelogenous leukemia. Transplant Cell Ther. 2021;27:841–50.

20. Fisch P, Moris A, Rammensee HG, Handgretinger R. Inhibitory MHC class I receptors on γδ T cells in tumour immunity and autoimmunity. Immunol Today. 2000;21:187–91.

21. Dolstra H, Fredrix H, van der Meer A, de Witte T, Figdor C, van de Wiel-van Kemenade E. TCRγδ cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transplant. 2001;27:1087–93.

22. Handgretinger R, Lang P, André MC. Exploitation of natural killer cells for the treatment of acute leukemia. Blood. 2016;127:3341–9.

23. Perko R, Kang G, Sunkara A, Leung W, Thomas PG, Dallas MH. Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia. Biol Blood Marrow Transplant. 2015;21:130–6.

24. Zheng J, Liu Y, Lau YL, Tu W. γδ-T cells: an unpolished sword in human anti-infection immunity. Cell Mol Immunol. 2013;10:50–7.

25. Knight A, Madrigal AJ, Grace S, Sivakumaran J, Kottaridis P, Mackinnon S, et al. The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood. 2010;116:2164–72.

26. Schepers W, van Dorp S, Kersting S, Pietersma F, Lindemans C, Hol S, et al. γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia. 2013;27:1328–38.

27. Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenscher R, Ditschkowski M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011;118:1402–12.

28. Farnault L, Gertner-Dardenne J, Gondois-Rey F, Michel G, Chambost H, Hirsch I, et al. Clinical evidence implicating gamma-delta T cells in EBV control following cord blood transplantation. Bone Marrow Transplant. 2013;48:1478–9.

29. Ravens S, Schultz-Florio C, Raha S, Sandrock I, Drenker M, Oberdörfer L, et al. Human γδ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. Nat Immunol. 2017;18:393–401.

30. Liu J, Gao H, Xu LP, Mo XD, Liu R, Liang S, et al. Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2+ T cells activities after hematopoietic transplantation for blood malignancies. J Immunother Cancer. 2020;8:e00208.

31. Arruda LCM, Gaballa A, Uhlin M. Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis. Blood Adv. 2019;3:3436–48.

32. Barfield RC, Otto M, Houston J, Holladay M, Geiger T, Martin J, et al. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy. 2004;6:1–6.

33. Chaleff S, Otto M, Barfield RC, Lyengar R, Martin J, et al. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy. 2007;9:746–54.

34. Otto M, Barfield RC, Lyengar R, Gatewood J, Müller I, Holladay MS, et al. Human γδ T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation. J Immunother. 2005;28:73–8.
35. Minculescu L, Sengelov H, Marquart HV, Ryder LP, Fischer-Nielsen A, Haastrop E. Granulocyte colony-stimulating factor effectively mobilizes TCR γδ and NK cells providing an allograft potentially enhanced for the graft-versus-leukemia effect for allogeneic stem cell transplantation. Front Immunol. 2021;12:625165.

36. Bethge WA, Eyrich M, Mielke S, Meisel R, Niederwieser D, Schlegel PG, et al. Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. Bone Marrow Transplant. 2021;[Epub ahead of print].

37. de Witte MA, Janssen A, Nijskens K, Karaiskaki F, Swanenberg L, van Rhenen A, et al. αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies. Blood Adv. 2021;5:240–9.

38. Lang P, Feuchtinger T, Teltschik HM, Schwinger W, Schlegel P, Pfeiffer M, et al. Improved immune recovery after transplantation of TCRalphabeta/CD19-depleted allografts from haploidentical donors in pediatric patients. Bone Marrow Transplant. 2015;50:S6–10.

39. Maschan M, Sheliakhova L, Ilushina M, Kurnikova E, Boyakova E, Balashov D, et al. TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. Bone Marrow Transplant. 2016;51:668–74.

40. Airoldi I, Bertaina A, Prigione I, Zorzoli A, Pagliara D, Cocco C, et al. γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+ CD19+ lymphocytes. Blood. 2015;125:2349–58.

41. Airoldi I, Bertaina A, Prigione I, Zorzoli A, Petretto A, Barbarito G, Inglese E, Merli P, et al. Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor. Oncoimmunology. 2016;6:e1216291.

42. Merli P, Algeri M, Galaverna F, Milano GM, Bertaina V, Biagini S, et al. Immune modulation properties of zoledronic acid on TcRγδ T-lymphocytes after TcRαβ/CD19-depleted haploidentical stem cell transplantation: an analysis on 46 pediatric patients affected by acute leukemia. Front Immunol. 2020;11:699.

43. Burnham RE, Zoine JT, Story JY, Garimalla SN, Gibson G, Rae A, et al. Characterization of donor variability for γδ T cell ex vivo expansion and development of an allogeneic γδ T cell immunotherapy. Front Med (Lausanne). 2020;7:588453.

44. Aehnlich P, Carnaz Simões AM, Skadborg SK, Holmen Olofsson G, Thor Straten P. Expansion with IL-15 increases cytotoxicity of Vγ9Vδ2 T cells and is associated with higher levels of cytotoxic molecules and T-bet. Front Immunol. 2020;11:1868.

45. Chen HC, Eling N, Martinez-Jimenez CP, O’Brien LM, Carbonaro V, Marioni JC, et al. IL-7-dependent compositional changes within the γδ T cell pool in lymph nodes during ageing lead to an unbalanced anti-tumour response. EMBO Rep. 2019;20:e47379.

46. Airoldi I, Bertaina A, Prigione I, Zorzoli A, Pagliara D, Cocco C, et al. γδ T cell homeostasis is controlled by IL-7 and IL-15 together with subset-specific factors. J Immunol. 2005;174:4606–12.

47. Barros MS, de Araújo ND, Magalhães-Gama F, Pereira Ribeiro TL, Alves Hanna FS, Tarragô AM, et al. γδ T cells for leukemia immunotherapy: new and expanding trends. Front Immunol. 2021;12:729085.

48. Capietto AH, Martinet L, Fournié JJ. Stimulated γδ T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer. J Immunol. 2011;187:1031–8.

49. Hoeres T, Pretscher D, Holzmann E, Smetak M, Birkmann J, Triebel J, et al. Improving immunotherapy against B-cell malignancies using γδ T-cell-specific stimulation and therapeutic monoclonal antibodies. J Immunother. 2019;42:331–44.

50. Seidel UJ, Vogt F, Grosse-Hovest L, Jung G, Handgretinger R, Lang P. γδ T cell-mediated antibody-dependent cellular cytotoxicity with CD19 antibodies assessed by an impedance-based label-free real-time cytotoxicity assay. Front Immunol. 2014;5:618.
51. Schlegel P, Jung G, Lang AM, Döring M, Schulte JH, Ebinger M, et al. ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL. Bone Marrow Transplant. 2019;54:689–93.

52. Madhok A, Bhat SA, Philip CS, Sureshbabu SK, Chiplunkar S, Galande S. Transcriptome signature of Vγ9Vδ2 T cells treated with phosphoantigens and notch inhibitor reveals interplay between TCR and notch signaling pathways. Front Immunol. 2021;12:660361.

53. Pauza CD, Liou ML, Lahusen T, Xiao L, Lapidus RG, Cairo C, et al. Gamma delta T cell therapy for cancer: it is good to be local. Front Immunol. 2018;9:1305.

54. Schilbach K, Frommer K, Meier S, Handgretinger R, Eyrich M. Immune response of human propagated γδ-T-cells to neuroblastoma recommend the Vδ1+ subset for γδ-T-cell-based immunotherapy. J Immunother. 2008;31:896–905.

55. Almeida AR, Correia DV, Fernandes-Platzgummer A, da Silva CL, da Silva MG, Anjos DR, et al. Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion/differentiation and preclinical proof of concept. Clin Cancer Res. 2016;22:5795–804.

56. Rozenbaum M, Meir A, Aharon Y, Itzhaki O, Schachter J, Bank I, et al. Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia. Front Immunol. 2020;11:1347.

57. Nishimoto KP, Barca T, Azameera A, Makkouk A, Romero JM, Bai L, et al. Allogeneic CD20-targeted gammadelta T cells exhibit innate and adaptive antitumor activity in preclinical B-cell lymphoma models. Clin Transl Immunology. 2022;11:e1373.

58. Makkouk A, Yang X, Barca T, Lucas A, Turkoz M, Wong J, et al. 119 ADI-002: an IL-15 armored allogeneic ‘off-the-shelf’ Vδ1 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3). J Immunother Cancer. 2021;9:A128.

59. Makkouk A, Yang XC, Barca T, Lucas A, Turkoz M, Wong JTS, et al. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J Immunother Cancer. 2021;9:e003441.